Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Servier to Acquire Day One Biopharmaceuticals for $2.5 Billion – French Pharma Expands U.S. Oncology Presence with ADC Assets

Fineline Cube Mar 9, 2026
Company Deals

Boan Biotech Partners with DP Technology on AI4S Drug Discovery – Antibody, ADC, and TCE Pipeline Acceleration

Fineline Cube Mar 6, 2026
Company Deals

AstraGenomics and Kactus Forge Gene Editing Partnership – Global Commercial Rights and Manufacturing Scale-Up for Nucleic Acid Therapeutics

Fineline Cube Mar 5, 2026
Company Deals

Rallybio to Acquire Candid Therapeutics in $700M+ Merger – Creates Leading Autoimmune T‑Cell Engager Company

Fineline Cube Mar 5, 2026
Company Deals

Edding Genor Expands ANGPTL3 siRNA Rights to Global – Restructures Napeptide Partnership

Fineline Cube Mar 4, 2026
Policy / Regulatory

NMPA Removes OCALIVA from GQCE Reference List – Obeticholic Acid Stripped Over Safety Concerns, Benefit-Risk Profile

Fineline Cube Mar 10, 2026
Company Drug

HutchMed Withdraws TAZVERIK from China – Safety Concerns Drive Global Recall of Epizyme/Ipsen EZH2 Inhibitor

Fineline Cube Mar 10, 2026
Company Drug

Fosun Pharma’s HLX316 Wins NMPA Approval – First-in-Class B7-H3 Sialidase Heterodimer Targets Advanced Solid Tumors

Fineline Cube Mar 10, 2026
Company Drug

GSK’s Blenrep and Star Pharma’s Topiramate Solution Target Priority Review in China

Fineline Cube Dec 18, 2024

The China’s Center for Drug Evaluation (CDE) website has signaled that GlaxoSmithKline’s (GSK; NYSE: GSK)...

Company Drug

Sciwind Biosciences’ Ecnoglutide Accepted for Review by NMPA for Weight Management

Fineline Cube Dec 18, 2024

Sciwind Biosciences Co., Ltd has received a significant boost as the National Medical Products Administration...

Company Deals

Blackstone and Bain Capital Submit Final Bids for Mitsubishi Tanabe Pharma

Fineline Cube Dec 18, 2024

In a significant development in the alternative asset management sector, companies such as Blackstone and...

Company Drug

Everest Medicines’ Velsipity NDA for Ulcerative Colitis Accepted by China’s NMPA

Fineline Cube Dec 17, 2024

China-based Everest Medicines (HKG: 1952) has announced that the National Medical Products Administration (NMPA) has...

Drug

AstraZeneca’s ALXN2350 Selected for CDE’s Rare Disease Drug Development Program

Fineline Cube Dec 17, 2024

The Center for Drug Evaluation (CDE) in China has announced its intention to include AstraZeneca’s...

Policy / Regulatory

NMPA’s CDE Releases Draft Proposal for Benefit-Risk Assessment in Global Drug Development

Fineline Cube Dec 17, 2024

The Center for Drug Evaluation of the National Medical Products Administration (NMPA) has issued the...

Hospital

Perennial Real Estate Holdings’ Tianjin Hospital Earns Medical Practice License

Fineline Cube Dec 17, 2024

Singapore-based Perennial Real Estate Holdings Limited has announced that its Perennial General Hospital in Tianjin...

Company Drug

MSD Halts Development of Vibostolimab and Favezelimab Due to Trial Setbacks

Fineline Cube Dec 17, 2024

US pharmaceutical giant Merck, Sharp & Dohme (MSD; NYSE: MRK) has revealed its decision to...

Company Deals

Adcendo ApS Expands Partnership with Biocytogen to Enhance ADC Pipeline

Fineline Cube Dec 17, 2024

China’s Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) has announced that Denmark-based Adcendo ApS has...

Company Medical Device

MicroPort CardioFlow’s VitaFlow Liberty Receives Marketing Approval in Turkey

Fineline Cube Dec 17, 2024

China-based MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160) has announced that its second-generation transcatheter aortic...

Company Drug

Vcanbio’s VUM02 Secures NMPA Approval and FDA ODD for Cirrhosis and aGvHD

Fineline Cube Dec 17, 2024

China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced significant progress for...

Company

Novo Nordisk Invests DKK 8.5 Billion in New Odense Manufacturing Facility

Fineline Cube Dec 17, 2024

Denmark-based pharmaceutical giant Novo Nordisk A/S (NYSE: NVO) is making a significant investment in its...

Company Drug

Johnson & Johnson Submits sBLA to FDA for Simponi in Pediatric Ulcerative Colitis

Fineline Cube Dec 17, 2024

US pharmaceutical major Johnson & Johnson (J&J, NYSE: JNJ) has announced the submission of a...

Company Drug

J&J’s SC Amivantamab Faces Complete Response Letter from FDA for NSCLC Treatment

Fineline Cube Dec 17, 2024

Johnson & Johnson (J&J, NYSE: JNJ) has announced that the Biologics License Application (BLA) filed...

Company Drug

Grand Pharmaceutical’s GPN01768 Accepted for Review by NMPA for Demodex Blepharitis Treatment

Fineline Cube Dec 17, 2024

Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) has announced that the National Medical Products Administration...

Company Drug

Jiangsu Hengrui’s Trastuzumab Rezetecan on Track for NMPA’s Breakthrough Therapy Designation

Fineline Cube Dec 17, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276), a leading pharmaceutical company based in China, has...

Company Drug

Abbisko Therapeutics Receives NMPA Approval for Irpagratinib Regulatory Study

Fineline Cube Dec 17, 2024

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that it has received approval...

Company Drug

Vocabria Receives Positive CHMP Opinion for HIV Treatment in Adolescents

Fineline Cube Dec 17, 2024

GSK plc (NYSE: GSK) has announced that ViiV Healthcare, an HIV specialist majority owned by...

Company Drug

GSK’s Jemperli Receives Positive CHMP Opinion for Endometrial Cancer Indication Extension

Fineline Cube Dec 17, 2024

The UK-based pharmaceutical giant GSK (NYSE: GSK) has received a positive opinion from the European...

Company Drug

GSK’s Jemperli Receives FDA Breakthrough Therapy Designation for Rectal Cancer Treatment

Fineline Cube Dec 17, 2024

UK-based pharmaceutical giant GSK (NYSE: GSK) has announced that it has received Breakthrough Therapy Designation...

Posts pagination

1 … 210 211 212 … 632

Recent updates

  • NMPA Removes OCALIVA from GQCE Reference List – Obeticholic Acid Stripped Over Safety Concerns, Benefit-Risk Profile
  • HutchMed Withdraws TAZVERIK from China – Safety Concerns Drive Global Recall of Epizyme/Ipsen EZH2 Inhibitor
  • Fosun Pharma’s HLX316 Wins NMPA Approval – First-in-Class B7-H3 Sialidase Heterodimer Targets Advanced Solid Tumors
  • Hengrui’s HRS9531 Wins NMPA Approval for CKD Trial – Dual GIPR/GLP-1R Agonist Expands Beyond Diabetes and Obesity
  • Merck KGaA Cuts SpringWorks Hippo Inhibitor and Hengrui PARP1 Program – R&D Pipeline Optimization Ditches €3.7 Billion in Acquired Assets
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

NMPA Removes OCALIVA from GQCE Reference List – Obeticholic Acid Stripped Over Safety Concerns, Benefit-Risk Profile

Company Drug

HutchMed Withdraws TAZVERIK from China – Safety Concerns Drive Global Recall of Epizyme/Ipsen EZH2 Inhibitor

Company Drug

Fosun Pharma’s HLX316 Wins NMPA Approval – First-in-Class B7-H3 Sialidase Heterodimer Targets Advanced Solid Tumors

Company Drug

Hengrui’s HRS9531 Wins NMPA Approval for CKD Trial – Dual GIPR/GLP-1R Agonist Expands Beyond Diabetes and Obesity

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.